ConductScience.org, home

Paper17538157

Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.

Forastiere AA and 1 other. J Clin Oncol, 2007. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. Papers, record 17538157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538157

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
0.84
iCite
Revised in PubMed
2018-12-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Forastiere AAArlene A
2Burtness BABarbara A

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
QuinazolinesMajor topic
Antibodies, Monoclonal, Humanized
Cetuximab
Erlotinib Hydrochloride
Gene Dosage
Humans
Polymerase Chain Reaction
Quality of Life

Source PubMed

Download CSV of topics

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment on17538160Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.https://conductscience.org/library/papers/17538160PubMed
Comment on17538161
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
https://conductscience.org/library/papers/17538161PubMed
Comment on17538162
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
https://conductscience.org/library/papers/17538162PubMed
Comment on17538163Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.https://conductscience.org/library/papers/17538163PubMed
Comment on17538164Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.https://conductscience.org/library/papers/17538164PubMed

Download CSV of comments and corrections

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
36579667EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models.Oncol Rep2023https://conductscience.org/library/papers/36579667PubMed
33540470A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.Mol Oncol2021https://conductscience.org/library/papers/33540470PubMed
29230548
Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.
Support Care Cancer2018https://conductscience.org/library/papers/29230548PubMed
28810546Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells.Exp Ther Med2017https://conductscience.org/library/papers/28810546PubMed
26883159Interaction of EGFR to δ-catenin leads to δ-catenin phosphorylation and enhances EGFR signaling.Sci Rep2016https://conductscience.org/library/papers/26883159PubMed
25622907RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.Neoplasia2015https://conductscience.org/library/papers/25622907PubMed
24602316MiRNA-125a-5p: a regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma.Cancer Cell Int2014https://conductscience.org/library/papers/24602316PubMed
23599382Deficiency of renal cortical EGF increases ENaC activity and contributes to salt-sensitive hypertension.J Am Soc Nephrol2013https://conductscience.org/library/papers/23599382PubMed
22851748Enterococcus faecalis enhances cell proliferation through hydrogen peroxide-mediated epidermal growth factor receptor activation.Infect Immun2012https://conductscience.org/library/papers/22851748PubMed
20302655Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer.Mol Cancer2010https://conductscience.org/library/papers/20302655PubMed
20158573Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy.J Cell Mol Med2010https://conductscience.org/library/papers/20158573PubMed
19216848Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies.Curr Oncol Rep2009https://conductscience.org/library/papers/19216848PubMed
18577994Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.Br J Cancer2008https://conductscience.org/library/papers/18577994PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538157

GET https://conductscience.org/api/papers/v1/17538157/authors